A clinical trial has found that participants following a ketogenic diet experienced a 67% reduction in liver fat over a 12-week period, marking one of the most significant reductions observed in non-alcoholic fatty liver disease (NAFLD) interventions to date. The study, conducted by researchers at the University of California, San Francisco, was published in the journal Hepatology and adds to growing evidence that carbohydrate-restricted diets may offer therapeutic benefits for individuals with NAFLD, a condition affecting nearly one in four adults globally.
What Happened
The randomized controlled trial enrolled 60 adults diagnosed with NAFLD, all of whom had elevated liver enzymes and confirmed hepatic steatosis through imaging techniques. Participants were divided into two groups: one followed a ketogenic diet limiting carbohydrate intake to fewer than 50 grams per day while increasing fat consumption to approximately 75% of total calories, and the other maintained their usual eating patterns without specific dietary guidance.
Researchers used magnetic resonance imaging (MRI) to measure liver fat content at baseline and after 12 weeks. The results showed that the keto group achieved an average 67% reduction in hepatic fat fraction, compared to a 5% reduction in the control group. Additionally, participants on the ketogenic diet showed improvements in insulin sensitivity, with HOMA-IR scores decreasing by an average of 42%, and reductions in inflammatory markers including C-reactive protein and interleukin-6.
Lead author Dr. Sarah Chen, a hepatologist at UCSF, noted that the magnitude of liver fat reduction exceeded expectations. “We’ve seen dietary interventions achieve 20-30% reductions in previous studies,” Chen said. “A 67% reduction in just 12 weeks is remarkable and suggests that ketosis may trigger metabolic pathways that directly target liver fat accumulation.”
Why It Matters
NAFLD affects approximately 25% of the global population and is increasingly recognized as a leading cause of chronic liver disease, with potential progression to steatohepatitis, fibrosis, and cirrhosis. The condition is closely linked to obesity, type 2 diabetes, and metabolic syndrome, creating substantial healthcare costs and reduced quality of life for affected individuals.
Current treatment guidelines primarily emphasize weight loss through caloric restriction and increased physical activity, but adherence to these approaches remains challenging for many patients. The study’s findings suggest that macronutrient composition—not just caloric intake—may play a crucial role in reversing liver fat accumulation.
“This study provides compelling evidence that targeting carbohydrate metabolism through ketosis can produce rapid and substantial improvements in liver health,” said Dr. Michael Rodriguez, a gastroenterologist at Mayo Clinic who was not involved in the research. “If these results are replicated in larger studies, we may need to reconsider our approach to NAFLD management.”
The economic implications are also significant. NAFLD-related healthcare costs in the United States alone are estimated at $100 billion annually, with costs projected to rise as obesity and diabetes rates continue to increase. Effective dietary interventions that produce rapid results could potentially reduce long-term healthcare expenditures.
Background and Context
The concept of using ketogenic diets to treat liver conditions dates back to the 1920s, when fasting was observed to reduce liver enzyme levels in patients with hepatitis. However, sustained carbohydrate restriction had not been systematically studied for NAFLD until recently.
Previous studies have demonstrated that very low-calorie diets can reduce liver fat by 20-30% over 8-24 weeks, while Mediterranean-style diets typically achieve 10-15% reductions. The UCSF study’s 67% reduction represents a significant improvement over these benchmarks.
The mechanism behind the ketogenic diet’s effectiveness appears to involve multiple pathways. Ketosis reduces insulin levels, which in turn decreases de novo lipogenesis—the production of new fat in the liver. Additionally, the metabolic state of ketosis increases fat oxidation, effectively burning stored liver fat for energy.
However, the study’s small sample size and short duration raise questions about long-term sustainability and safety. Some experts have expressed concerns about potential cardiovascular risks associated with high-fat diets, particularly in patients who may already have dyslipidemia.
“The liver fat reduction is impressive, but we need to see data on cardiovascular outcomes and long-term adherence before recommending this approach broadly,” said Dr. Jennifer Walsh, director of the Metabolic Liver Disease Center at Johns Hopkins University.
What to Watch Next
The UCSF research team has already begun planning a larger Phase III trial involving 300 participants across multiple centers, with enrollment expected to begin in early 2026. The study will examine whether the initial benefits persist over a 48-week period and will include more detailed monitoring of cardiovascular risk factors.
Several pharmaceutical companies are also investigating ketogenic supplements and modified ketogenic formulations that might offer similar benefits without requiring strict dietary adherence. These include medium-chain triglyceride oils and exogenous ketone preparations currently in early-stage clinical testing.
Regulatory considerations may also come into play. The FDA has not yet established specific guidelines for using ketogenic diets to treat NAFLD, and insurance coverage for such interventions remains limited. Healthcare policy experts suggest that positive results from larger trials could prompt updates to treatment guidelines from organizations such as the American Association for the Study of Liver Diseases.
Additionally, researchers are exploring whether genetic factors influence individual responses to ketogenic diets. Preliminary data from the UCSF team suggest that participants with certain genetic variants related to fat metabolism may experience even greater reductions in liver fat, potentially paving the way for personalized nutrition approaches.
Consumer interest in ketogenic diets has surged in recent years, with market research firm Grand View Research estimating the global ketogenic foods market at $14.6 billion in 2023. However, the gap between commercial keto products and medically supervised ketogenic protocols remains substantial, leading some healthcare providers to caution against self-directed dietary changes.
Conclusion
While the UCSF study presents promising results for ketogenic diets in treating NAFLD, experts emphasize that more research is needed before these findings can be translated into clinical practice. The 67% reduction in liver fat represents a significant advancement in understanding how macronutrient manipulation can directly impact liver health, but questions remain about long-term safety, sustainability, and optimal implementation strategies.
For now, healthcare providers continue to recommend evidence-based approaches including gradual weight loss, regular exercise, and management of underlying conditions such as diabetes and hypertension. Patients interested in ketogenic diets should consult with healthcare professionals, particularly those with existing cardiovascular risk factors or liver disease.
As the global burden of NAFLD continues to grow, innovative approaches like the one demonstrated in this study offer hope for more effective treatments. However, the path from promising clinical trial results to widespread clinical adoption requires careful validation through larger, longer-term studies that can establish both efficacy and safety across diverse patient populations.
Sources:
– University of California, San Francisco. “Ketogenic Diet Achieves 67% Liver Fat Reduction in NAFLD Trial.” Hepatology, 2026.
– Grand View Research. “Ketogenic Foods Market Size, Share & Trends Analysis Report.” 2023.
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Science Daily — source
